Short answer
Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Board expanded from eight to nine directors, adding Suzanne Topalian, M.D. through the 2028 annual meeting.
Vir Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from eight to nine directors, adding Suzanne Topalian, M.D. through the 2028 annual meeting
- Topalian joins the Science and Technology Committee, strengthening board-level scientific oversight
- New director receives standard cash compensation, stock options and restricted stock units under Vir’s policy
- Appointment included standard director indemnification, with no disclosed related-party transactions or selection arrangements
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vir Biotechnology, Inc. 8-K filings
Get the next VIR 8-K as it lands
Follow VIR for push alerts, or ask the research agent what this filing means.